WO2006032216A3 - Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas - Google Patents

Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas Download PDF

Info

Publication number
WO2006032216A3
WO2006032216A3 PCT/CU2005/000008 CU2005000008W WO2006032216A3 WO 2006032216 A3 WO2006032216 A3 WO 2006032216A3 CU 2005000008 W CU2005000008 W CU 2005000008W WO 2006032216 A3 WO2006032216 A3 WO 2006032216A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
pharmaceutical compositions
hsp60
apl
mechanisms
Prior art date
Application number
PCT/CU2005/000008
Other languages
English (en)
French (fr)
Other versions
WO2006032216A2 (es
Inventor
Horta Maria Del Carm Dominguez
Palomares Gabriel Ramon Padron
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Alba Jose Suarez
Original Assignee
Ct Ingenieria Genetica Biotech
Horta Maria Del Carm Dominguez
Palomares Gabriel Ramon Padron
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Alba Jose Suarez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05794474.6T priority Critical patent/DK1803732T3/da
Priority to BR122018077204A priority patent/BR122018077204B8/pt
Priority to AT05794474T priority patent/ATE546462T1/de
Priority to JP2007532752A priority patent/JP4755649B2/ja
Priority to KR1020077008682A priority patent/KR101054332B1/ko
Priority to AU2005287757A priority patent/AU2005287757B2/en
Priority to EP05794474A priority patent/EP1803732B1/en
Priority to MX2007003624A priority patent/MX2007003624A/es
Application filed by Ct Ingenieria Genetica Biotech, Horta Maria Del Carm Dominguez, Palomares Gabriel Ramon Padron, Marin Nelia Lopez, Perez Norailys Lorenzo, Betancourt Ariana Barbera, Garcia Ariadna Hernandez, Cordova Vivian Morera, Diaz Carelia Cosme, Garcia Nelson J Merino, Bonachea Ariel Vazquez, Alba Jose Suarez filed Critical Ct Ingenieria Genetica Biotech
Priority to CA2581110A priority patent/CA2581110C/en
Priority to BRPI0515893A priority patent/BRPI0515893B8/pt
Priority to CN2005800403891A priority patent/CN101065398B/zh
Priority to US11/663,603 priority patent/US8383771B2/en
Priority to ES05794474T priority patent/ES2386498T3/es
Publication of WO2006032216A2 publication Critical patent/WO2006032216A2/es
Publication of WO2006032216A3 publication Critical patent/WO2006032216A3/es
Priority to US12/649,687 priority patent/US8324164B2/en
Priority to AU2010219312A priority patent/AU2010219312B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos de la proteína humana de estrés térmico de 60 kDa que constituyen epitopes para células T, así como péptidos derivados de ellos, los cuales están modificados en los sitios de contacto con la molécula MHC, útiles para inducir mecanismos de tolerancia periférica, en particular mecanismos inductores de anergia o mediados por clones de células T regulatorias en pacientes con Artritis Reumatoide. La invención también refiere composiciones farmacéuticas que comprenden tales péptidos para tratamiento de la Artritis Reumatoide.
PCT/CU2005/000008 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas WO2006032216A2 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2581110A CA2581110C (en) 2004-09-24 2005-09-22 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
BR122018077204A BR122018077204B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
BRPI0515893A BRPI0515893B8 (pt) 2004-09-24 2005-09-22 peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica.
KR1020077008682A KR101054332B1 (ko) 2004-09-24 2005-09-22 Ｈｓｐ60의 펩티드 및 이들의 유도형 ａｐｌ 및 약학적조성물
AU2005287757A AU2005287757B2 (en) 2004-09-24 2005-09-22 Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
EP05794474A EP1803732B1 (en) 2004-09-24 2005-09-22 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions
MX2007003624A MX2007003624A (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
DK05794474.6T DK1803732T3 (da) 2004-09-24 2005-09-22 Peptider og derivater af APL-TYPE af HSP60 og famaceutiske sammensætninger
AT05794474T ATE546462T1 (de) 2004-09-24 2005-09-22 Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen
JP2007532752A JP4755649B2 (ja) 2004-09-24 2005-09-22 Ｈｓｐ６０のペプチド及びａｐｌ型誘導体並びに医薬組成物
CN2005800403891A CN101065398B (zh) 2004-09-24 2005-09-22 Hsp60的肽和apl型衍生物及药物组合物
US11/663,603 US8383771B2 (en) 2004-09-24 2005-09-22 Altered peptide ligand derived from HSP60 and pharmaceutical compositions
ES05794474T ES2386498T3 (es) 2004-09-24 2005-09-22 Péptidos y derivados tipo APL de Hsp60 y composiciones farmacéuticas
US12/649,687 US8324164B2 (en) 2004-09-24 2009-12-30 Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions
AU2010219312A AU2010219312B2 (en) 2004-09-24 2010-09-06 Peptides and APL-type derivatives of HSP60 and pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
CU2004-0207 2004-09-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/663,603 A-371-Of-International US8383771B2 (en) 2004-09-24 2005-09-22 Altered peptide ligand derived from HSP60 and pharmaceutical compositions
US12/649,687 Division US8324164B2 (en) 2004-09-24 2009-12-30 Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2006032216A2 WO2006032216A2 (es) 2006-03-30
WO2006032216A3 true WO2006032216A3 (es) 2007-05-18

Family

ID=40273413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2005/000008 WO2006032216A2 (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP1803732B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101035283B1 (es)
CN (2) CN101935345B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BR122018077204B8 (es)
CA (2) CA2797769C (es)
CU (1) CU23504A1 (es)
DK (2) DK1803732T3 (es)
ES (2) ES2445707T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423220B1 (en) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
US8680241B2 (en) * 2009-09-06 2014-03-25 Protab Ltd. Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof
WO2011059758A2 (en) * 2009-10-28 2011-05-19 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011966A1 (en) * 1995-09-27 1997-04-03 Peptide Therapeutic Limited Polypeptides and their use in treatment and prophylaxis of auto-immune disease
WO2001043691A2 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
JP2005503533A (ja) 2001-01-19 2005-02-03 ケンブリッジ サイエンティフィック， インコーポレイテッド 骨粗鬆症の診断方法および処置方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011966A1 (en) * 1995-09-27 1997-04-03 Peptide Therapeutic Limited Polypeptides and their use in treatment and prophylaxis of auto-immune disease
WO2001043691A2 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHOI J-I ET AL: "Epitope mapping of Porphyromonas gingivalis heat-shock protein and human heat-shock protein in human atherosclerosis.", JOURNAL OF DENTAL RESEARCH. DEC 2004, vol. 83, no. 12, December 2004 (2004-12-01), pages 936 - 940, XP002371464, ISSN: 0022-0345 *
JOOSTEN I ET AL: "DIRECT BINDING OF AUTOIMMUNE DISEASE RELATED T CELL EPITOPES TO PURIFIED LEWIS RAT MHC CLASS II MOLECULES", 1 May 1994, INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, PAGE(S) 751-759, ISSN: 0953-8178, XP000590812 *
KAMPHUIS S S ET AL: "V1.2. recognition of multiple hsp60 epitopes in patients with juvenile idiopathic arthritis opens the way for antigen-specific immunotherapy.", ANNALS OF THE RHEUMATIC DISEASES. OCT 2001, vol. 60 Suppl 2, October 2001 (2001-10-01), pages II7 - II15, XP002371476, ISSN: 0003-4967 *
KAMPHUIS SYLVIA ET AL: "Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis.", LANCET. 2005 JUL 2-8, vol. 366, no. 9479, 2 July 2005 (2005-07-02), pages 50 - 56, XP002371481, ISSN: 1474-547X *
PRAKKEN BERENT J ET AL: "Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 23 MAR 2004, vol. 101, no. 12, 23 March 2004 (2004-03-23), pages 4228 - 4233, XP002371463, ISSN: 0027-8424 *
QUINTANA FRANCISCO J ET AL: "DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 OCT 2003, vol. 171, no. 7, 1 October 2003 (2003-10-01), pages 3533 - 3541, XP002371462, ISSN: 0022-1767 *
RAMMENSEE HANS-GEORG ET AL: "SYFPEITHI: Database for MHC ligands and peptide motifs", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 50, no. 3-4, November 1999 (1999-11-01), pages 213 - 219, XP002183663, ISSN: 0093-7711 *
REIZIS B ET AL: "The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI.", INTERNATIONAL IMMUNOLOGY DEC 1996, vol. 8, no. 12, December 1996 (1996-12-01), pages 1825 - 1832, XP002421975, ISSN: 0953-8178 *
SINGH H ET AL: "ProPred: prediction of HLA-DR binding sites.", BIOINFORMATICS (OXFORD, ENGLAND) DEC 2001, vol. 17, no. 12, December 2001 (2001-12-01), pages 1236 - 1237, XP002371461, ISSN: 1367-4803 *

Also Published As

Publication number Publication date
ZA200702938B (en) 2008-08-27
ES2445707T3 (es) 2014-03-04
DK1803732T3 (da) 2012-05-29
CA2581110A1 (en) 2006-03-30
KR20100028645A (ko) 2010-03-12
AU2010219312A1 (en) 2010-09-23
EP2371847A1 (en) 2011-10-05
CA2797769A1 (en) 2006-03-30
CN101935345A (zh) 2011-01-05
EP1803732A2 (en) 2007-07-04
US20090171069A1 (en) 2009-07-02
AU2010219312B2 (en) 2011-10-06
US8383771B2 (en) 2013-02-26
DK2371847T3 (da) 2014-02-03
ATE546462T1 (de) 2012-03-15
KR101035283B1 (ko) 2011-05-18
WO2006032216A2 (es) 2006-03-30
US20100144642A1 (en) 2010-06-10
AR074924A2 (es) 2011-02-23
EP1803732B1 (en) 2012-02-22
BR122018077204B1 (pt) 2020-01-28
JP4755649B2 (ja) 2011-08-24
EP2371847B1 (en) 2013-11-20
CA2797769C (en) 2015-09-15
KR101054332B1 (ko) 2011-08-04
US8324164B2 (en) 2012-12-04
CU23504A1 (es) 2010-04-13
BRPI0515893B1 (pt) 2020-09-15
CN101065398A (zh) 2007-10-31
ES2386498T3 (es) 2012-08-22
BR122018077204B8 (pt) 2021-07-27
AU2005287757A1 (en) 2006-03-30
BRPI0515893B8 (pt) 2021-05-25
BRPI0515893A8 (pt) 2019-01-02
BRPI0515893A (pt) 2008-08-12
KR20070073787A (ko) 2007-07-10
MX2007003624A (es) 2007-06-13
CA2581110C (en) 2013-04-02
AR051928A1 (es) 2007-02-21
CN101935345B (zh) 2013-12-11
JP2008514553A (ja) 2008-05-08
RU2007115411A (ru) 2008-10-27
AU2005287757B2 (en) 2010-07-29
RU2361877C2 (ru) 2009-07-20
CN101065398B (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
WO2006032216A3 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
MX2010003574A (es) Anticuerpos il-23.
WO2008124647A3 (en) Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
HK1101131A1 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
WO2005063820A3 (en) Il-7 fusion proteins
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
IL187168A (en) Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
ATE503765T1 (de) Neue antimalaria-impfstoffzusammensetzungen und anwendungen davon
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2005085280A3 (en) HUMAN cDNA CLONES COMPRISING POLYNUCLEOTIDES ENCODING POLYPEPTIDES AND METHODS OF THEIR USE
WO2009087467A3 (en) Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2008005470A3 (en) Polypeptides that bind membrane proteins
JOP20190101A1 (ar) أنظمة علاج

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007532752

Country of ref document: JP

Ref document number: 2581110

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003624

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2665/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005794474

Country of ref document: EP

Ref document number: 1020077008682

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005287757

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007115411

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005287757

Country of ref document: AU

Date of ref document: 20050922

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200580040389.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005794474

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11663603

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0515893

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 1020107001135

Country of ref document: KR

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref country code: BR

Free format text: ANULADA A PUBLICACAO CODIGO 1.3.1 NA RPI NO 2504 DE 02/01/2019 POR TER SIDO INDEVIDA.